Twist Bioscience Corporation $TWST Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its position in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 190.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 283,910 shares of the company’s stock after purchasing an additional 186,294 shares during the period. Russell Investments Group Ltd. owned approximately 0.45% of Twist Bioscience worth $54,863,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Pier 88 Investment Partners LLC bought a new stake in Twist Bioscience during the 3rd quarter valued at $676,000. Lisanti Capital Growth LLC acquired a new position in Twist Bioscience during the third quarter worth $5,584,000. Ritholtz Wealth Management acquired a new position in Twist Bioscience during the third quarter worth $327,000. Lido Advisors LLC bought a new position in shares of Twist Bioscience in the third quarter valued at $8,162,000. Finally, Fulcrum Asset Management LLP bought a new position in shares of Twist Bioscience in the third quarter valued at $8,668,000.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $111.60 on Monday. The company has a market capitalization of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25. The stock has a fifty day simple moving average of $150.23 and a 200 day simple moving average of $93.07. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience’s revenue for the quarter was up 26.7% on a year-over-year basis. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -1.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TWST. Guggenheim lifted their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Robert W. Baird lowered their target price on shares of Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday. UBS Group initiated coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. Canaccord Genuity Group dropped their price target on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday. Finally, TD Cowen cut their price target on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating for the company in a research note on Friday. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $141.00.

View Our Latest Stock Report on Twist Bioscience

Insider Transactions at Twist Bioscience

In related news, insider Dennis Cho sold 949 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $128,494.60. Following the transaction, the insider directly owned 62,840 shares of the company’s stock, valued at $8,508,536. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,462 shares of the firm’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $156.30, for a total transaction of $384,810.60. Following the transaction, the chief financial officer directly owned 98,114 shares in the company, valued at $15,335,218.20. The trade was a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is owned by insiders.

Top Twist Bioscience Stories

These are some of the TWST stories that stood out recently:

Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Featured Articles

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.